MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Core Insights - The study demonstrated that Ketamir-2 is safe and well tolerated at all dose levels, with no severe or clinically significant adverse effects observed [1] - The drug exhibited rapid and predictable absorption, supporting a favorable duration of action for once-daily dosing [1] - Ketamir-2 does not present CNS side effects typically associated with ketamine [1]